These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 22941027)

  • 41. Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.
    McDonald MM; Reagan MR; Youlten SE; Mohanty ST; Seckinger A; Terry RL; Pettitt JA; Simic MK; Cheng TL; Morse A; Le LMT; Abi-Hanna D; Kramer I; Falank C; Fairfield H; Ghobrial IM; Baldock PA; Little DG; Kneissel M; Vanderkerken K; Bassett JHD; Williams GR; Oyajobi BO; Hose D; Phan TG; Croucher PI
    Blood; 2017 Jun; 129(26):3452-3464. PubMed ID: 28515094
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bone disease in multiple myeloma.
    Drake MT
    Oncology (Williston Park); 2009 Dec; 23(14 Suppl 5):28-32. PubMed ID: 20128326
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The impact of response on bone-directed therapy in patients with multiple myeloma.
    Larocca A; Child JA; Cook G; Jackson GH; Russell N; Szubert A; Gregory WM; Brioli A; Owen RG; Drayson MT; Wu P; Palumbo A; Boccadoro M; Davies FE; Morgan GJ
    Blood; 2013 Oct; 122(17):2974-7. PubMed ID: 23974194
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical trials of bisphosphonates in multiple myeloma.
    Mahindra A; Pozzi S; Raje N
    Clin Adv Hematol Oncol; 2012 Sep; 10(9):582-7. PubMed ID: 23073123
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bisphosphonate guidelines for treatment and prevention of myeloma bone disease.
    Lee OL; Horvath N; Lee C; Joshua D; Ho J; Szer J; Quach H; Spencer A; Harrison S; Mollee P; Roberts AW; Talaulikar D; Brown R; Augustson B; Ling S; Jaksic W; Gibson J; Kalff A; Johnston A; Kalro A; Ward C; Prince HM; Zannettino A
    Intern Med J; 2017 Aug; 47(8):938-951. PubMed ID: 28782211
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mechanisms of bone destruction in multiple myeloma.
    Terpos E; Christoulas D; Gavriatopoulou M; Dimopoulos MA
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28940410
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid.
    Cetiner S; Sucak GT; Kahraman SA; Aki SZ; Kocakahyaoglu B; Gultekin SE; Cetiner M; Haznedar R
    J Bone Miner Metab; 2009; 27(4):435-43. PubMed ID: 19240969
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis.
    Lopez-Olivo MA; Shah NA; Pratt G; Risser JM; Symanski E; Suarez-Almazor ME
    Support Care Cancer; 2012 Nov; 20(11):2985-98. PubMed ID: 22956190
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aetiology of bone disease and the role of bisphosphonates in multiple myeloma.
    Ashcroft AJ; Davies FE; Morgan GJ
    Lancet Oncol; 2003 May; 4(5):284-92. PubMed ID: 12732166
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective.
    Delea TE; Rotter J; Taylor M; Chandiwana D; Bains M; El Ouagari K; Kaura S; Morgan GJ
    J Med Econ; 2012; 15(3):454-64. PubMed ID: 22316275
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel therapeutic targets in myeloma bone disease.
    Webb SL; Edwards CM
    Br J Pharmacol; 2014 Aug; 171(16):3765-76. PubMed ID: 24750110
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of bisphosphonates in breast cancer.
    Theriault RL
    J Natl Compr Canc Netw; 2003 Apr; 1(2):232-41. PubMed ID: 19768882
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.
    Tan M; Kalin-Hajdu E; Narayan R; Wong SW; Martin TG
    J Oncol Pharm Pract; 2019 Jul; 25(5):1253-1257. PubMed ID: 30005587
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
    Xie J; Namjoshi M; Wu EQ; Parikh K; Diener M; Yu AP; Guo A; Culver KW
    J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease.
    Terpos E; Berenson J; Cook RJ; Lipton A; Coleman RE
    Leukemia; 2010 May; 24(5):1043-9. PubMed ID: 20376081
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Advances in imaging and the management of myeloma bone disease.
    Terpos E; Moulopoulos LA; Dimopoulos MA
    J Clin Oncol; 2011 May; 29(14):1907-15. PubMed ID: 21483016
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bisphosphonate therapy in multiple myeloma: past, present, future.
    Jantunen E
    Eur J Haematol; 2002; 69(5-6):257-64. PubMed ID: 12460229
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
    Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
    Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Further analyses of the Myeloma IX Study.
    Morgan GJ
    Lancet; 2011 Aug; 378(9793):768-9. PubMed ID: 21872746
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.